,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-06-17 07:00:00,The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig .,0.11987075954675674,0.004934975877404213,0.8751943111419678,neutral,0.11493578553199768
1,2018-06-17 07:00:00,"This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.",0.44186264276504517,0.010622658766806126,0.5475146770477295,neutral,0.4312399923801422
2,2018-06-17 07:00:00,CHARLES RIVER LABORATORIES INTL.,0.015591262839734554,0.012962020002305508,0.9714467525482178,neutral,0.0026292428374290466
3,2018-06-17 07:00:00,INC ( CRL ) is a mid-cap growth stock in the Biotechnology & Drugs industry.,0.7222952246665955,0.012309230864048004,0.26539552211761475,positive,0.7099859714508057
4,2018-06-17 07:00:00,The rating according to our strategy based on Martin Zweig is 85% based on the firm's underlying fundamentals and the stock's valuation.,0.0344078429043293,0.005085877142846584,0.9605062007904053,neutral,0.02932196483016014
5,2018-06-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
6,2018-06-17 07:00:00,"Company Description: Charles River Laboratories International, Inc. is an early-stage contract research company.",0.030281540006399155,0.005514189135283232,0.9642042517662048,neutral,0.024767350405454636
7,2018-06-17 07:00:00,"The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice ( GLP ) and non-GLP, which supports its clients from target identification through non-clinical development.",0.10538201034069061,0.0043517523445189,0.8902661800384521,neutral,0.10103026032447815
8,2018-06-17 07:00:00,"The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).",0.019753118976950645,0.005813432391732931,0.974433422088623,neutral,0.013939686119556427
9,2018-06-17 07:00:00,The RMS segment includes Research Models and Research Model Services.,0.012622000649571419,0.006800569593906403,0.9805773496627808,neutral,0.005821431055665016
10,2018-06-17 07:00:00,The DSA segment includes Discovery Services and Safety Assessment.,0.013655124232172966,0.006797403562813997,0.9795475602149963,neutral,0.006857720669358969
11,2018-06-17 07:00:00,"The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing.",0.01320639718323946,0.006981737911701202,0.9798118472099304,neutral,0.006224659271538258
12,2018-06-17 07:00:00,The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.,0.07489992678165436,0.004556737374514341,0.920543372631073,neutral,0.07034318894147873
13,2018-06-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
14,2018-06-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
15,2018-06-17 07:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CENTENE CORP ( CNC ) is a large-cap growth stock in the Healthcare Facilities industry.",0.41314172744750977,0.009952259249985218,0.5769060254096985,neutral,0.403189480304718
16,2018-06-17 07:00:00,The rating according to our strategy based on Martin Zweig is 85% based on the firm's underlying fundamentals and the stock's valuation.,0.0344078429043293,0.005085877142846584,0.9605062007904053,neutral,0.02932196483016014
17,2018-06-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
18,2018-06-17 07:00:00,Company Description: Centene Corporation is a healthcare company.,0.013636989519000053,0.007707209791988134,0.9786558151245117,neutral,0.005929779727011919
19,2018-06-17 07:00:00,"The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals.",0.05731837823987007,0.004353087395429611,0.9383285045623779,neutral,0.05296529084444046
20,2018-06-17 07:00:00,The Company operates through two segments: Managed Care and Specialty Services.,0.01519644446671009,0.006824484094977379,0.9779791235923767,neutral,0.008371960371732712
21,2018-06-17 07:00:00,"The Company's Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children's Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.",0.025052782148122787,0.005645122844725847,0.9693021178245544,neutral,0.019407659769058228
22,2018-06-17 07:00:00,"Its Specialty Services segment consists of its specialty companies offering a range of healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations, as well as to its own subsidiaries.",0.018496008589863777,0.005602935794740915,0.9759010076522827,neutral,0.01289307326078415
23,2018-06-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
24,2018-06-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
25,2018-06-17 07:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INTUITIVE SURGICAL, INC. ( ISRG ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.6697328686714172,0.010893653146922588,0.3193734586238861,positive,0.658839225769043
26,2018-06-17 07:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
27,2018-06-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
28,2018-06-17 07:00:00,"Company Description: Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories.",0.02185518853366375,0.006197228562086821,0.9719475507736206,neutral,0.015657959505915642
29,2018-06-17 07:00:00,"The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system.",0.020238682627677917,0.007399392314255238,0.9723619222640991,neutral,0.01283929031342268
30,2018-06-17 07:00:00,"The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports.",0.02189486473798752,0.010379241779446602,0.9677258729934692,neutral,0.011515622958540916
31,2018-06-17 07:00:00,"The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition ( HD ) vision.",0.14674335718154907,0.005833636038005352,0.8474230170249939,neutral,0.14090971648693085
32,2018-06-17 07:00:00,"Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System.",0.08619140088558197,0.005270529538393021,0.9085380434989929,neutral,0.08092087507247925
33,2018-06-17 07:00:00,The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.,0.01875384896993637,0.00609822990372777,0.9751479625701904,neutral,0.012655619531869888
34,2018-06-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
35,2018-06-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
36,2018-06-17 07:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

USANA HEALTH SCIENCES, INC. (USNA) is a mid-cap growth stock in the Biotechnology & Drugs industry.",0.37837666273117065,0.009092488326132298,0.6125308871269226,neutral,0.36928418278694153
37,2018-06-17 07:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
38,2018-06-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
39,2018-06-17 07:00:00,"Company Description: USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products.",0.02331777662038803,0.00604233518242836,0.9706399440765381,neutral,0.01727544143795967
40,2018-06-17 07:00:00,"The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.",0.03240102902054787,0.005791601724922657,0.961807370185852,neutral,0.026609428226947784
41,2018-06-17 07:00:00,"Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other.",0.02712702378630638,0.005093457642942667,0.9677794575691223,neutral,0.022033566609025
42,2018-06-17 07:00:00,Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year.,0.09235405176877975,0.004843621514737606,0.9028022885322571,neutral,0.08751042932271957
43,2018-06-17 07:00:00,Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs.,0.03855755925178528,0.0045529925264418125,0.9568895101547241,neutral,0.034004565328359604
44,2018-06-17 07:00:00,"Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.",0.04603436589241028,0.00476089445874095,0.949204683303833,neutral,0.04127347096800804
45,2018-06-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
46,2018-06-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
47,2018-06-17 07:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

IDEXX LABORATORIES, INC. (IDXX) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.5883432626724243,0.009509949944913387,0.4021468162536621,positive,0.5788333415985107
48,2018-06-17 07:00:00,The rating according to our strategy based on Martin Zweig is 77% based on the firm's underlying fundamentals and the stock's valuation.,0.03034227155148983,0.005309665575623512,0.9643480181694031,neutral,0.025032605975866318
49,2018-06-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
50,2018-06-17 07:00:00,"Company Description: IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets.",0.02600177936255932,0.006143143400549889,0.9678550958633423,neutral,0.01985863596200943
51,2018-06-17 07:00:00,The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.,0.04908337444067001,0.004796919412910938,0.9461197257041931,neutral,0.04428645595908165
52,2018-06-17 07:00:00,"Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements.",0.02575812116265297,0.005367340054363012,0.9688745737075806,neutral,0.02039078064262867
53,2018-06-17 07:00:00,"Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.",0.02197411097586155,0.0052581229247152805,0.97276771068573,neutral,0.016715988516807556
54,2018-06-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
55,2018-06-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
56,2018-06-17 07:00:00,"EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Martin Zweig has returned 488.40% vs. 177.83% for the S&P 500.",0.7736400961875916,0.1489042043685913,0.07745572924613953,positive,0.6247358918190002
57,2018-06-17 07:00:00,"For more details on this strategy, click here

About Martin Zweig : During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest.",0.8395671248435974,0.017058880999684334,0.1433740258216858,positive,0.8225082159042358
58,2018-06-17 07:00:00,"Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses.",0.1772042065858841,0.007844403386116028,0.8149514198303223,neutral,0.16935980319976807
59,2018-06-17 07:00:00,"He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in ""Dirty Harry"", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.",0.08425553888082504,0.01607971452176571,0.8996647596359253,neutral,0.06817582249641418
60,2018-06-17 07:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
61,2018-06-17 07:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751807361841202,0.01020655408501625,0.9022754430770874,neutral,0.07731151580810547
62,2018-06-17 07:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221812710165977,0.018771812319755554,0.9720063209533691,neutral,-0.009549999609589577
